krizotinib - Keresési eredmények

Európai Unió - magyar - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - karcinóma, nem kissejtes tüdő - daganatellenes szerek - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Európai Unió - magyar - EMA (European Medicines Agency)

alecensa

roche registration gmbh - alectinib hidroklorid - karcinóma, nem kissejtes tüdő - daganatellenes szerek - az alecensa monoterápia az anaplastic lymphoma kináz (alk) -poszív, nem kissejtes tüdőrák (nsclc) felnőtt betegek első vonalbeli kezelésére javallt,. alecensa, mint monoterápia kezelésére felnőtt betegek aik‑pozitív előrehaladott nsclc korábban kezelt crizotinib.

Európai Unió - magyar - EMA (European Medicines Agency)

lorviqua

pfizer europe ma eeig - lorlatinib - karcinóma, nem kissejtes tüdő - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Európai Unió - magyar - EMA (European Medicines Agency)

alunbrig

takeda pharma a/s - brigatinib - karcinóma, nem kissejtes tüdő - daganatellenes szerek - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.